UK markets open in 4 minutes

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
8,746.00+98.00 (+1.13%)
At close: 4:43PM BST
Sign in to post a message.
  • B
    Bryan
    very interesting that they didn't post this article under AZN's summary... very interesting indeed.. keeping it hush hush... AZN might be out of the Covid game for good after this..

    https://www.nytimes.com/2020/09/19/health/astrazeneca-vaccine-safety-blueprints.html
    Experts are concerned that the company has not been more forthcoming about two participants who became seriously ill after getting its experimental vaccine.
    Experts are concerned that the company has not been more forthcoming about two participants who became seriously ill after getting its experimental vaccine.
    www.nytimes.com
  • r
    ram
    LONDON: AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after getting the green light from safety watchdogs, the company said on Saturday (Sep 12).
  • E
    Ella
    Semi Annual dividend of .44 paid yesterday.
  • B
    Ben
    money doing better here than in tech right now. up 1% so far today. 1 day closer to the release of the phase 2/3 vaccine trial results which should cause this to jump up nicely. glta!
  • G
    GEO77
    "After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine," AZN says.
  • g
    georgejjl
    The Oxford vaccine

    Astrazeneca could screen out vaccine recipients for John Cunningham virus (JCV) prior to getting the vaccine.

    Quote:
    London: Two days after the worrying news of the clinical trials of Oxford-AstraZeneca’s COVID vaccine candidate being halted, the drugmaker revealed that a participant had developed severe neurological symptoms.

    It was found that a woman reported symptoms consistent with transverse myelitis, a rare inflammation of the spinal cord. However, it has not been confirmed that it’s indeed transverse myelitis and more tests are being carried.

    https://odishabytes.com/astrazeneca-reveals-why-its-covid-19-vaccine-was-halted/

    Quote:
    JC Virus Induced Longitudinally Extensive Transverse Myelitis in Immunocompromised Patient

    https://scholarlycommons.henryford.com/cgi/viewcontent.cgi?article=1057&context=merf2019caserpt

    Good luck and GOD bless,
  • B
    Ben
    at the rate this has been slowly climbing up, i think we test the $58-$59 range next week. glta!
  • J
    Jordy
    Normal pauses happens frequently in P3 trials especially the ones woth over 30K participants. With 30K testing , then people get sick and they always need to pause to see if its the vaccine or some other illness that occured. 30.000 people is a lot of people. Nothing special in the pharma world. The results are still good. I have been listening some podcast of renowned professor virologists from medical universities and doctors from the Netherlands, Astra is still one of the leading vaccines and are confident by the end of the year it will be available.
  • K
    Kale
    That patient was diagnosed with multiple sclerosis, everyone relax. These are simply precautionary measures and nothing more than that. Phase 3 will still be done by the end of the year. This is not a get rich quick stock, patience is key.
  • d
    dec5th1933
    I do not understand who AZN continues to move down, or not move at least a little bit up, upon some of the good news that has come out recently. I get it is a large company, and is not going to give you the double digit swings that we see in smaller stocks (notably the COVID pharma plays). However, I would think that even given the fact that it takes a lot for a large stock to move, the fact that we've had a lot of good news regarding Phase 3 trials starting, fast-track likelihood in the US, lung cancer drug approval, diabetes drug extending kidney disease survival rates, increased orders for COVID vaccine...I don't get why the stock isn't slowly moving upward in the last 6 weeks. I get that there may be a lot of people playing with the more volatile pharma stock picks to try to get some quick gains, but the bigger money - I would think - would be investing more in safer plays, like AZN.

    Again...I get it takes more to move a bigger stock like AZN - but I don't get the lack of slow but stead trending upwards over the last 6 weeks. Even if AZN's COVID drug is effective and gets fast-tracked, given the lack of movement we've seen, I really don't have much confidence it would move this stock more than 2-4%.

    Anyone have any thoughts here?
  • J
    Jordy
    Stock manipulating.

    AZN is the real deal. Europe bought themselves in. Docters speak promissing on it and they will deliver before the end of the year.

    Yesterday on a highly valued talk show in the Netherlands a doctor with a renowned track record was interviewed about his work at the front line of covid in the UK in charge of 17 hospitals. He presented a clear story about rhr vaccines and marker AZN as rhe absolute leader. Oxford makes it AZN produces it already in full orders and invests in it as they are pretty sure its getting P3 and approval. Already 10.000s are tested according to him including himself and its just matter of protocols. AZN would never take a risk producing if they didnt know this would be the vaccine to work with as they AZN is the manifacturer not the inventor kf this vaccine, oxford UNI is.
  • S
    S
    ”...from the hill article : This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."
    The statement said it is possible the illness in one of the participants in the trial is not even caused by the vaccine. "In large trials illnesses will happen by chance but must be independently reviewed to check this carefully," the company said. "We are working to expedite the review of the single event to minimise any potential impact on the trial timeline."
    - so in short: this is no Putin’s vaccine - they are just doing the right thing in a right way
  • X
    Xpensive-Wino
    https://finance.yahoo.com/news/astrazeneca-imfinzi-trial-shows-survival-120004816.html
  • A
    Adam
    EASY 10%+ on Monday thank you AZN!
  • S
    Steven
    Just not in New York. https://www.business-standard.com/article/markets/astrazeneca-pharma-hit-fresh-record-high-of-rs-4-489-stock-surge-15-120090700709_1.html
    The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.
    The stock of the company was trading higher for the fifth straight day, surging 26 per cent during the period.
    www.business-standard.com
  • F
    Francofab10
    Adverse event in COVID-19 study unlikely related vaccine - Oxford
  • b
    barry
    This vaccine will now NEVER get fda approval. I sold all mine in ah. This will all come out tomorrow.
  • v
    vasan
    AZN has accumulated huge orders and who is going to fill it ? It's going to be none other than Novavax because both of them have manufacturing contract with the largest vaccine manufacturer in the world SII (Serum Institute of India). SII can switch production lines of AZN to NVAX within weeks If not days said Adar Poonawalla, CEO of SII.
  • F
    Football is it
    AZN is not a covid vaccine stock. It is a large Pharma company that was $51 before covid.
  • r
    ram
    https://www.scmp.com/news/world/europe/article/3101330/coronavirus-oxford-restarts-trial-astrazeneca-vaccine-after-pause
    Final-stage trials in the UK to resume after it was halted over concerns about a participant who fell ill.
    Final-stage trials in the UK to resume after it was halted over concerns about a participant who fell ill.
    www.scmp.com
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more